Sunshine Biopharma Inc
NASDAQ:SBFM

Watchlist Manager
Sunshine Biopharma Inc Logo
Sunshine Biopharma Inc
NASDAQ:SBFM
Watchlist
Price: 1.28 USD 4.07% Market Closed
Market Cap: 6.3m USD

Sunshine Biopharma Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sunshine Biopharma Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Sunshine Biopharma Inc
NASDAQ:SBFM
Operating Income
-$4.9m
CAGR 3-Years
-7%
CAGR 5-Years
-62%
CAGR 10-Years
-20%
Theratechnologies Inc
TSX:TH
Operating Income
$8.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Operating Income
-$79.2m
CAGR 3-Years
-40%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Operating Income
$87m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Operating Income
-$340.8m
CAGR 3-Years
-45%
CAGR 5-Years
-63%
CAGR 10-Years
-48%
Spectral Medical Inc
TSX:EDT
Operating Income
-CA$6.7m
CAGR 3-Years
16%
CAGR 5-Years
5%
CAGR 10-Years
4%
No Stocks Found

Sunshine Biopharma Inc
Glance View

Market Cap
5.8m USD
Industry
Biotechnology

Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.

SBFM Intrinsic Value
Not Available

See Also

What is Sunshine Biopharma Inc's Operating Income?
Operating Income
-4.9m USD

Based on the financial report for Sep 30, 2025, Sunshine Biopharma Inc's Operating Income amounts to -4.9m USD.

What is Sunshine Biopharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-20%

Over the last year, the Operating Income growth was 1%. The average annual Operating Income growth rates for Sunshine Biopharma Inc have been -7% over the past three years , -62% over the past five years , and -20% over the past ten years .

Back to Top